Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
DEPO DepoMed Inc. daily Stock Chart
DepoMed Inc.
Index- P/E33.62 EPS (ttm)0.48 Insider Own0.60% Shs Outstand60.48M Perf Week5.22%
Market Cap976.15M Forward P/E9.46 EPS next Y1.71 Insider Trans-3.97% Shs Float59.91M Perf Month-6.49%
Income49.60M PEG1.12 EPS next Q0.29 Inst Own98.40% Short Float18.03% Perf Quarter-15.23%
Sales426.20M P/S2.29 EPS this Y173.30% Inst Trans-0.03% Short Ratio5.93 Perf Half Y-46.22%
Book/sh5.66 P/B2.85 EPS next Y116.22% ROA4.80% Target Price27.13 Perf Year-9.63%
Cash/sh2.85 P/C5.66 EPS next 5Y30.00% ROE14.00% 52W Range13.27 - 33.74 Perf YTD-10.98%
Dividend- P/FCF11.05 EPS past 5Y46.60% ROI25.60% 52W High-52.16% Beta1.30
Dividend %- Quick Ratio1.60 Sales past 5Y46.60% Gross Margin88.20% 52W Low21.63% ATR1.15
Employees324 Current Ratio1.70 Sales Q/Q103.70% Oper. Margin31.40% RSI (14)50.24 Volatility6.41% 8.97%
OptionableYes Debt/Eq2.38 EPS Q/Q-281.80% Profit Margin11.60% Rel Volume1.22 Prev Close16.80
ShortableYes LT Debt/Eq2.38 EarningsFeb 22 AMC Payout0.00% Avg Volume1.82M Price16.14
Recom2.20 SMA204.27% SMA50-7.03% SMA200-27.85% Volume2,225,056 Change-3.93%
Jan-07-16Initiated Mizuho Neutral $19
Dec-03-15Resumed Morgan Stanley Equal-Weight $21
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Nov-04-15Initiated Cantor Fitzgerald Buy
Oct-21-15Reiterated RBC Capital Mkts Sector Perform $32 → $26
Jul-30-15Downgrade RBC Capital Mkts Outperform → Sector Perform $26 → $32
Jul-24-15Reiterated WallachBeth Hold $26 → $33
Jul-14-15Reiterated ROTH Capital Buy $28.50 → $33
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
Apr-06-15Reiterated ROTH Capital Buy $27 → $30
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Feb-03-16 08:00AM  Depomed to Present at Healthcare Conferences in February GlobeNewswire
Jan-27-16 08:26AM  Depomed Announces Save the Date for 2016 Analyst and Investor Day at noodls -8.78%
08:00AM  Depomed Announces Save the Date for 2016 Analyst and Investor Day GlobeNewswire
Jan-21-16 04:15PM  Depomed, Inc.: Price momentum supported by strong fundamentals
Jan-19-16 08:01AM  DEPOMED INC Files SEC form 8-K, Other Events -7.12%
Jan-14-16 10:20AM  The #JPM16 wrap: A new reality, Invitae's big test and Horizon's silence at +6.33%
Jan-07-16 05:59AM  Coverage initiated on DepoMed by Mizuho -7.07%
Jan-06-16 08:02AM  Why Horizon Pharma plc Shares Jumped 68% in 2015 at Motley Fool
Jan-04-16 08:00AM  Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal GlobeNewswire
Dec-29-15 08:11AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 29, 2015
Dec-22-15 12:00PM  Rising Demand for Pain Medicine Could Boost These Stocks In 2016 at Motley Fool
Dec-14-15 09:27AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 14, 2015
Dec-11-15 05:14PM  Horizon Pharma acquires Crealta Holdings for $510 million -6.38%
03:25PM  Horizon Buying Maker Of Gout Drug For $510 Million at Investor's Business Daily
10:40AM  Depomed, Inc. Earnings Analysis: Q3, 2015 By the Numbers
08:44AM  [$$] Horizon Pharma to Buy Crealta for $510 Million at The Wall Street Journal
Dec-09-15 09:03AM  Direction of Market Influences - Research on Depomed, Novavax, Boyd Gaming and Owens-Illinois Accesswire
Dec-08-15 01:17PM  DEPOMED INC Financials +8.63%
Dec-04-15 03:00PM  DEPO: Depomed Enhances its Pain Management Franchise by Acquiring Cebranopadol
08:40AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 4, 2015
Nov-25-15 01:57PM  Horizon Drops DepoMed Acquisition: Helps IBB Mid-Cap Performance
01:32PM  Does Your iPad Know Magic Tricks? at MarketWatch
Nov-24-15 08:00AM  Depomed to Present at Four Investor Events in December PR Newswire +6.15%
Nov-22-15 07:00AM  3 Specialty-Drug Makers Trying to Spark Investor Interest -- Are They Buys? at Motley Fool
Nov-20-15 04:42PM  Chipotle and Nike are big market movers
03:51PM  Is Depomed Inc (DEPO) Going to Burn These Hedge Funds? at Insider Monkey
02:23PM  DEPOMED INC Files SEC form 8-K, Other Events
01:33PM  Horizon Pharma Stock Rises After Depomed Chase Ends at Investor's Business Daily
11:19AM  Depomed (DEPO) Stock Lower as Horizon Pharma Withdraws Takeover Bid at TheStreet
08:55AM  Top Analyst Upgrades and Downgrades: DepoMed, Gap, Intel, IBM, Nimble Storage, Workday and Many More at 24/7 Wall St.
03:30AM  Hostile bidder pulls out of $2 billion buyout of East Bay drug maker at
01:39AM  PRESS DIGEST - Wall Street Journal - Nov 20 Reuters
Nov-19-15 10:31PM  [$$] Horizon Pharma Withdraws Bid for Depomed at The Wall Street Journal
10:05PM  Depomed Comments on Horizon Withdrawal of Offer to Acquire Company PR Newswire
09:08PM  Horizon drops hostile bid for Depomed after judge's ruling
08:30PM  Horizon Pharma withdraws offer for Depomed after court ruling
Nov-18-15 04:00PM  East Bay biotech buys drug as shareholders mull $2 billion hostile bid at
Nov-17-15 05:00PM  Depomed Inc Corporate Call to Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal scheduled for 5:00 pm ET today
04:25PM  Depomed Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal PR Newswire
Nov-13-15 05:17PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.03%
04:45PM  $2 billion offer extended by hostile bidder of East Bay drug maker at
08:00AM  Depomed Named to Deloitte's 2015 Technology Fast 500 List of Fastest Growing Companies in North America PR Newswire
Nov-11-15 04:00PM  Depomed to Present at the Stifel Healthcare Conference PR Newswire -6.18%
02:50PM  Here's Why DepoMed (DEPO) Stock Is Falling Today at TheStreet
01:45PM  Why Horizon and Express Scripts Woes Might Make DepoMed Dirt Cheap at 24/7 Wall St.
01:04PM  Specialty Pharmacy Ties Claim Next Victim; Horizon Falls 17%; DepoMed Selloff "Unwarranted," Says Janney at
Nov-10-15 04:15PM  DepoMed Reports Strong Financials for Fiscal Third Quarter of 2015 +5.47%
01:34PM  3 Midsize Drug Stocks Moving On Q3 Reports at Investor's Business Daily
Nov-09-15 08:54PM  [$$] DepoMed Lifts 2015 Guidance at The Wall Street Journal
06:08PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report
05:11PM  Depomed reports 3Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance PR Newswire
07:07AM  Q3 2015 Depomed Inc Earnings Release - After Market Close
Nov-05-15 05:21PM  Valeant Said to Make Late Payments on $17 Million to PDL at Bloomberg
Nov-03-15 05:15PM  ISS and Glass Lewis Recommend Horizon Pharma Shareholders Vote AGAINST the Issuance of Horizon Shares in Connection with Horizon's Attempted Takeover of Depomed PR Newswire
04:00PM  Depomed to Report Third Quarter Fiscal Year 2015 Financial Results on Monday, November 9, 2015 PR Newswire
Oct-24-15 11:35AM  8 Fresh Analyst Picks Called to Rise 50% to 100% at 24/7 Wall St.
Oct-23-15 11:47AM  Horizon Pharma Counters Depomed Hit On Drug Pricing at Investor's Business Daily +9.93%
Oct-22-15 05:10PM  Beyond Hillary and Bernie, drug pricing at front of another campaign at
01:38PM  Noted Biotech Analyst Doesn't Think Valeant And Horizon Are Frauds, But Did Push A Line
10:59AM  Depomed Validates Horizon Pharma Rejection Offer
08:30AM  Depomed Comments on Recent Reports Regarding Horizon Pharma's Business Model PR Newswire
Oct-20-15 07:03PM  Pricing Concerns Continue To Hit Pharma Companies at The Wall Street Journal -17.14%
02:05PM  Whats The Deal With These Sinking Stocks? at Insider Monkey
Oct-19-15 09:07AM  Why GlaxoSmithKline Management Is Hopeful about Consumer Healthcare
Oct-17-15 01:41PM  3 Biotechs Stocks That We Think The Market Has All Wrong at Motley Fool
Oct-15-15 11:47AM  Depomed Issues Statement PR Newswire +5.10%
Oct-09-15 08:09AM  Horizon passes regulatory hurdle in pursuit of Depomed
Oct-06-15 11:55AM  DEPO: NUCYNTA Has the Blockbuster Potential -7.84%
Oct-01-15 10:10AM  Facing hostile takeover, East Bay drug company execs buy more stock at
10:08AM  How Did IBBs Top 5 Pharmaceutical Small Caps Perform?
Sep-30-15 04:08PM  Squashed Takeovers And Positive Test Results Propelling These Stocks Higher at Insider Monkey +21.61%
Sep-28-15 04:47PM  10 Stocks Moving In Monday's After-Hours Session -22.14%
03:41PM  War of words heats up in $2 billion East Bay drug company takeover bid at
06:30AM  Depomed Issues Statement on ISS Report PR Newswire
Sep-23-15 10:12AM  Stock to Watch: J.C. Penney, Heron Therapeutics, Intra-Cellular Therapies at The Wall Street Journal
09:24AM  Depomed Says It Receives Favorable Patent Decision at The Wall Street Journal
08:00AM  Depomed Announces Two Favorable Decisions in Inter Partes Review Proceedings Versus Endo Pharmaceuticals PR Newswire
Sep-22-15 01:25PM  Why DepoMed is Falling 10% Today at Motley Fool -12.68%
Sep-17-15 08:02AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-16-15 06:04AM  DEPOMED INC Files SEC form 8-K, Other Events
Sep-15-15 05:18PM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer PR Newswire
Sep-14-15 04:26PM  Depomed rejects Horizon's latest takeover offer
11:36AM  DepoMed Urges Holders to Reject Horizon Offer at The Wall Street Journal
08:00AM  Depomed's Board of Directors Rejects Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
Sep-10-15 08:00AM  Depomed to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-09-15 10:00AM  Depomed and The American Migraine Foundation Join Forces to Highlight Need for the Proper Diagnosis, Management and Treatment of Migraine PR Newswire
Sep-08-15 04:10PM  Pay no attention to that $2 billion offer, East Bay company tells shareholders at
10:11AM  Horizon takes hostile Depomed bid directly to shareholders
09:17AM  Depomed Issues Statement on Horizon Pharma plc's Unsolicited Exchange Offer PR Newswire
08:19AM  Horizon Pharma Begins Hostile Bid for Depomed After Rebuffs at Bloomberg
08:04AM  Horizon pushes hostile Depomed bid with shareholder offer
Sep-04-15 06:15PM  Mystery, intrigue as biotech M&A explodes at
Sep-02-15 08:00AM  Depomed's Expanded Portfolio Of Pain Management Products Led By The NUCYNTA® Franchise To Be Highlighted At PAINWeek® 2015 PR Newswire
Sep-01-15 01:46PM  Smart Money Vs. Retail Investors: Level the Playing Field
Aug-31-15 07:21AM  Depomed Sets Record Date in Response to Horizon Bid at The Wall Street Journal -5.11%
06:16AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-28-15 05:45PM  Wannabe buyer appeals to shareholders in contentious East Bay takeover at
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSVP, Business DevelopmentJan 11Option Exercise7.1218,180129,442170,737Jan 12 07:10 PM
Schoeneck James APresident and CEODec 28Option Exercise6.116,36538,8906,365Dec 28 07:24 PM
Moretti August JChief Financial Officer & SVPDec 16Option Exercise5.355,00026,75026,319Dec 17 12:31 PM
Moretti August JChief Financial Officer & SVPDec 03Sale18.1115,000271,59721,319Dec 03 06:32 PM
Schoeneck James APresident and CEOSep 29Option Exercise6.4263,561408,15863,561Sep 29 07:24 PM
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM
Vargas Thadd MSenior VP, BDApr 08Option Exercise6.1854,710338,010143,153Apr 09 04:50 PM